Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2026 | 2026-04-30 | $0 | reported | |
| FY 2025 | 2025-04-30 | $0 | reported | |
| FY 2024 | 2024-04-30 | $0 | reported | |
| FY 2023 | 2023-04-30 | $0 | reported | |
| FY 2022 | 2022-04-30 | $0 | reported | |
| FY 2021 | 2021-04-30 | $0 | reported | |
| FY 2020 | 2020-04-30 | $0 | reported | |
| FY 2019 | 2019-04-30 | $0 | reported | |
| FY 2018 | 2018-04-30 | $0 | reported | |
| FY 2017 | 2017-04-30 | $0 | reported | |
| FY 2016 | 2016-04-30 | $0 | reported | |
| FY 2015 | 2015-04-30 | $0 | reported |
PharmaCyte Biotech, Inc. · CIK 1157075 · Engraved from SEC EDGAR
Twelve months to Jul 31, 2026 · derived
PharmaCyte Biotech, Inc. is the 159th largest of the 175 covered companies the SEC files under this code, by market cap. SIC 2836
Latest filing Sep 14, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2026 | — | $401.63K | $401.63K | — | 10.74M sh | +58.0% | — |
| FY2025 | — | $2.54M | $2.54M | — | 6.80M sh | −11.9% | — |
| FY2024 | — | $28.20M | $28.20M | — | 7.71M sh | −12.2% | — |
| FY2023 | — | $13.56M | $13.56M | — | 8.78M sh | −57.7% | — |
| FY2022 | — | $0.00 | $0.00 | — | 20.75M sh | +0.1% | — |